Post Authorization Safety safety events analysis, Study of HCV patients among HCV December treated with patients who 2016 Eltrombopag: receive 12 months Multicentre, Prospective Eltrombopag in interim Observational Cohort the post analysis, June Study of approval, real 2017 Thrombocytopenic HCV world setting 18 months Patients Receiving interim Eltrombopag analysis, Pharmacoepidemiology October 2018 Category 3 Final report, Ongoing November 2019 HCV-TARGET: Proposed TEE and Hepatic Assess interim, Post Authorization Safety decompensation occurrence of October 2016 Study of HCV patients safety events Final report, treated with among HCV patients who October 2019 Eltrombopag: Hepatitis C receive Therapeutic Registry and Eltrombopag in Research Network the post Pharmacoepidemiology approval, real world setting Category 3 Ongoing HCV Research UK: TEE and Hepatic Assess First interim, Proposed Post decompensation occurrence of October 2016 Authorization Safety safety events Final report, Study of HCV patients among HCV October 2019 treated with patients who Eltrombopag receive Eltrombopag in Pharmacoepidemiology the post Category 3 approval, real world setting Ongoing Effectiveness of Key elements Measurement of Interim report, within the the April 2015 Eltrombopag Educational educational effectiveness of Final report, Materials for Hepatitis C materials the September associated including Hepatic Eltrombopag 2015 thrombocytopenia decompensation, Risk TEEs and fatal Minimisation Category 3 adverse events education Ongoing materials ELT116826 Safety in SAA Safety of April 2016 patients eltrombopag in Clinical SAA patients
Post Authorization Safety Study of HCV patients treated with Eltrombopag: Multicentre, Prospective Observational Cohort Study of Thrombocytopenic HCV Patients Receiving Eltrombopag Pharmacoepidemiology Category 3 Ongoing safety events among HCV patients who receive Eltrombopag in the post approval, real world setting analysis, December 2016 12 months interim analysis, June 2017 18 months interim analysis, October 2018 Final report, November 2019 HCV-TARGET: Proposed Post Authorization Safety Study of HCV patients treated with Eltrombopag: Hepatitis C Therapeutic Registry and Research Network Pharmacoepidemiology Category 3 Ongoing TEE and Hepatic decompensation Assess occurrence of safety events among HCV patients who receive Eltrombopag in the post approval, real world setting interim, October 2016 Final report, October 2019 HCV Research UK: Proposed Post Authorization Safety Study of HCV patients treated with Eltrombopag Pharmacoepidemiology Category 3 Ongoing TEE and Hepatic decompensation Assess occurrence of safety events among HCV patients who receive Eltrombopag in the post approval, real world setting First interim, October 2016 Final report, October 2019 Effectiveness of Eltrombopag Educational Materials for Hepatitis C associated thrombocytopenia Category 3 Ongoing Key elements within the educational materials including Hepatic decompensation, TEEs and fatal adverse events Measurement of the effectiveness of the Eltrombopag Risk Minimisation education materials Interim report, April 2015 Final report, September 2015 ELT116826 Clinical Safety in SAA patients Safety of eltrombopag in SAA patients April 2016
auspar-eltrombopag-160330.docx